Stock Financial Ratios and Split History

JUNO / Juno Therapeutics, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)10,096.52
Enterprise Value ($M)9,874.58
Book Value ($M)1,046.98
Book Value / Share9.02
Price / Book9.64
NCAV ($M)753.35
NCAV / Share6.49
Price / NCAV13.40
Income Statement (mra) ($M)
Net Income-437.11
Balance Sheet (mrq) ($M)
Cash & Equivalents0.00
Cash / Share0.00
Quick Ratio3.61
Current Ratio3.61
Share Statistics
Preferred Stock Shares Outstanding0
Common Stock Shares Outstanding114,313,000
Common Shares Outstanding116,105,371
Scoring Models
Piotroski F-Score1.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.41
Return on Assets (ROA)-0.32
Return on Equity (ROE)-0.41
Identifiers and Descriptors
Central Index Key (CIK)1594864
Industry Groups
SIC 2836 - Biological Products, Except Diagnostic Substances (Biotech)
Related CUSIPS
048205A10 48205A909 48205A959

Split History

Stock splits are used by Juno Therapeutics, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Peers - Biological Products, Except Diagnostic Substances (Biotech) (2836)

Related News Stories

Prothena Rallies on Multi-Year Collaboration With Celgene

18h zacks
Shares of Prothena Corporation plc (PRTA - Free Report) moved up 22.6% in the after-market trading session following the news of a global collaboration with biotech bigwig Celgene Corporation (CELG - Free Report) . (85-0)

Biotechs Approaching New Waters

2018-03-20 seekingalpha
The biotech sector also continues to benefit from potential M&A, faster drug approvals, strong risk appetite, and improving public sentiment. (727-2)

Despite Struggles Celgene Corporation Stock Is Still A Buy

2018-03-19 investorplace
Let’s just say, the last few quarters have not been biotech superstar Celgene’s (NASDAQ:CELG) best couple of months. The biotech stock has been hit by wave after wave of bad news, stumbles and declines. So much so, that investors have wiped off a collective $40 billion from CELG’s market cap since October. Today, Celgene stock can be had for prices not seen since 2014. (183-1)

Is Celgene Considering Going Private?

2018-03-15 biospace
Despite a deep pipeline and a market cap of $69.4 billion, Celgene shares are down 12 percent year to date. Its two biggest moneymakers, Revlimid and Pomalyst, will lose patent protection in the mid-2020s. As something of a thought exercise, Brian Abrahams, an analyst with RBC Capital Markets proposed a scenario where Celgene goes private in 2019 via leveraged buyout. (5-0)

Celgene LBO Talk Should Worry It - Bloomberg

2018-03-15 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (61-2)

CUSIP: 48205A109